Nicotine-based e-cigarettes likely increase risk for oral and lung cancers, and adjusting radiation after chemotherapy preserves low breast cancer recurrence rates.
The spring 2026 issue of Cancer Today included articles about using AI chatbots, cancer survivor—and “Survivor” winner—Ethan Zohn, and more.
Delaying immune-stimulating drugs after chemotherapy led to fewer cases of severe bone pain, and a two-drug regimen increased progression-free survival in lung cancer.
In March, AACR's journals editors highlighted studies on the development of pediatric leukemia, the use of low-dose tamoxifen, and more.
Relacorilant was approved for previously treated ovarian, fallopian tube, and peritoneal cancers. The U.S. Food and Drug Administration (FDA) has approved relacorilant (Lifyorli) in combination with nab-paclitaxel for the treatment of platinum-resistant epithelial ovarian,...
Simultaneously, previous accelerated approvals for nivolumab in relapsed/refractory advanced classical Hodgkin lymphoma were converted to full approvals. The U.S. Food and Drug Administration (FDA) approved nivolumab (Opdivo) in combination with the chemotherapy regimen doxorubicin,...
Therapy may reduce a chemotherapy-induced platelet disorder, and PSMA PET scans may help people with suspected prostate cancer forgo a biopsy.
Learn about smoldering myeloma and the first treatment approved by the U.S. Food and Drug Administration to prevent its progression to active multiple myeloma. Circulating throughout our bodies are various types of immune cells...
Treatment regimen approved for multiple myeloma, and people with melanoma who undergo sentinel node biopsy live longer.
Some people with prostate cancer may not need hormone therapy, and colorectal cancer cases shift increasingly to younger adults.
AACR Fellow Lewis C. Cantley, PhD, leads a national effort targeting triple-negative breast cancer and ovarian cancer with a novel drug combination.
Learn More